AIM: While both efficacy and safety of anti-PD-1 agents seem to be independent of previous treatment with anti-CTLA-4, limited data exist of efficacy and toxicity of ipilimumab after progression on anti-PD-1 therapy. This retrospective analysis describes the efficacy and safety of sequential therapy with ipilimumab in patients with metastatic melanoma who progressed on anti-PD-1 antibody. METHODS: Nine patients who progressed on anti-PD-1 therapy received four cycles of ipilimumab 3 mg/kg every 3 weeks. RESULTS: Two out of nine patients (2/9; 22.2%) showed a partial response, and seven patients (7/9; 77.8%) experienced disease progression. Median progression-free survival was 3.14 months (95% CI: 2.56-3.71), and the median overall survival since the start of anti-PD-1 therapy was 16.8 months (95% CI: 8.1-25.4). Five (5/9; 55.6%) patients experienced grade 3 immune-related adverse events. No grade 4 or 5 adverse events were reported. CONCLUSION: In this small retrospective series of cases, the efficacy of ipilimumab post-anti-PD-1 was similar to that described in the previous reports on ipilimumab.
AIM: While both efficacy and safety of anti-PD-1 agents seem to be independent of previous treatment with anti-CTLA-4, limited data exist of efficacy and toxicity of ipilimumab after progression on anti-PD-1 therapy. This retrospective analysis describes the efficacy and safety of sequential therapy with ipilimumab in patients with metastatic melanoma who progressed on anti-PD-1 antibody. METHODS: Nine patients who progressed on anti-PD-1 therapy received four cycles of ipilimumab 3 mg/kg every 3 weeks. RESULTS: Two out of nine patients (2/9; 22.2%) showed a partial response, and seven patients (7/9; 77.8%) experienced disease progression. Median progression-free survival was 3.14 months (95% CI: 2.56-3.71), and the median overall survival since the start of anti-PD-1 therapy was 16.8 months (95% CI: 8.1-25.4). Five (5/9; 55.6%) patients experienced grade 3 immune-related adverse events. No grade 4 or 5 adverse events were reported. CONCLUSION: In this small retrospective series of cases, the efficacy of ipilimumab post-anti-PD-1 was similar to that described in the previous reports on ipilimumab.
Authors: Dan A Erkes; Conroy O Field; Claudia Capparelli; Manoela Tiago; Timothy J Purwin; Inna Chervoneva; Adam C Berger; Edward J Hartsough; Jessie Villanueva; Andrew E Aplin Journal: Pigment Cell Melanoma Res Date: 2019-05-20 Impact factor: 4.693
Authors: Samantha Bowyer; Prashanth Prithviraj; Paul Lorigan; James Larkin; Grant McArthur; Victoria Atkinson; Michael Millward; Muoi Khou; Stefan Diem; Sangeetha Ramanujam; Ben Kong; Elizabeth Liniker; Alexander Guminski; Phillip Parente; Miles C Andrews; Sagun Parakh; Jonathan Cebon; Georgina V Long; Matteo S Carlino; Oliver Klein Journal: Br J Cancer Date: 2017-03-21 Impact factor: 7.640
Authors: Riccardo Marconcini; Francesco Spagnolo; Luigia Stefania Stucci; Simone Ribero; Elena Marra; Francesco De Rosa; Virginia Picasso; Lorenza Di Guardo; Carolina Cimminiello; Stefano Cavalieri; Laura Orgiano; Enrica Tanda; Laura Spano; Alfredo Falcone; Paola Queirolo Journal: Oncotarget Date: 2018-01-03